POm E-stimulation before whisker stimulus does not decrease cortical response magnitude and duration when AGA is applied in L1. by Carlos Castejon (2182382)

Quercetin decreases proliferation (A) and induces apoptosis (B) in cultured PASMC from control rats. by Daniel Morales-Cano (668199)

EWAT phospho-ACC (Ser79), phospho-AMPKα (Thr172) and phospho-PPARγ (Ser273) were decreased in LBW. by Ousseynou Sarr (577782)

Treatment with HBOT or PFD decreased IL-17A expression in the AD lesions. by Hyung-Ran Kim (532404)

Timeline of evaluation in nursing home residents (N = 37) by cohort (n = 2) and facility (n = 3)—Georgia, October 2020–July 2022. by Zeshan A. Chisty (18388200)

<i>Elsholtzia ciliata</i> extract (ECE) treatment decreases coronavirus-induced plaque formation. by Siyun Lee (17087351)

“…<b>(B)</b> ECE treatment decreases plaque formation in a dose-dependent manner. …”

Apoptotic volume decrease (AVD) current is stimulated in EYFP-LIPT2 expressing cells. by Emanuele Bernardinelli (4117372)

Sildenafil decreases intestinal transit time in a DSS-recovery model of IBS. by Sarah K. Sharman (3966476)

Algorithm operation steps. by Junyan Wang (4738518)

“…Experimental results demonstrate that SCI-YOLO11 achieves a 3.2% improvement over baseline models in terms of MAP@0.5 metric; precision and recall rates increase by 2.6% and 3.7%, respectively. …”

Overexpression of miR-520c-3p in DLBCL diminished colony formation in clonogenic assay and decreased tumor growth in xenograft model. by Krystyna Mazan-Mamczarz (37065)

Increased fat accumulation is not the result of increased food consumption or decreased physical activity. by Jessica N. Saykally (368303)

Decreased retinal cell density is associated with increased cell death in <i>Lrp2</i>^{<i>FoxG1</i>.<i>cre-KO</i>} mutant eyes. by Olivier Cases (760028)

Activated CD4+ CD45RO+ memory T-cells decrease secretion of soluble caspase-1 and P2X7R mRNA expression in monocytes leading to a reduced response upon ATP binding. by Vanessa Beynon (153924)

“…A significant decrease of soluble Caspase-1 in the supernatant of cells co-cultured with activated memory T-cells was observed both in the presence and absence of IFNβ; b) intracellular levels of pro-IL-1β measured with an ELISA specific for the immature precursor of IL-1β showed a significant increase in pro-IL-1β levels in the presence of human activated CD4+CD45RO+ memory T-cells (n = 3), cell lysates from adherent monocytes were obtained after removal of non-adherent T-cells after addition of LPS and prior to incubation with ATP c) the ratio of intracellular pro-IL-1β to released soluble Caspase-1 is significantly increased in the presence of human activated CD4+CD45RO+ memory T-cells (n = 3). d) <i>P2X7R</i> mRNA expression in monocytes cultured overnight with activated CD4+CD45RO+ memory T-cells is decreased with and without addition of exogenous IFNβ (n = 3), mRNA was isolated from adherent monocytes after removal of non-adherent T-cells after addition of LPS and prior to incubation with ATP (Data are shown as means ± SD of duplicate cultures; *p<0.05; **p<0.01 employing repeated measures ANOVA with post-hoc Bonferroni adjustment for multiple comparisons to avoid random correlations); e) Ca²⁺-influx measurement in monocytes cultured with activated human CD4+CD45RO+ memory T-cells in the presence of IFNβ demonstrates the absence of slow sustained Ca²⁺-influx mediated by ATP binding to the purinergic P2X7-receptor (representative of 3 independent experiments); f) Annexin V staining of monocytes coincubated with T-cells and stimulated with LPS was measured by flow cytometry (representative flow cytometry histogram of n = 5).…”

MSC treatment does not affect chronic LPS-induced decreased lung function. by P. Padmini S. J. Khedoe (4436458)

sEH inhibition decreased fasting glucose levels in type 2 diabetic mice. by Kristen L. Zuloaga (563616)

Discovery of Novel <i>N</i>‑Hydroxy-1,2,4-oxadiazole-5-formamides as ASM Direct Inhibitors for the Treatment of Atherosclerosis by Kan Yang (49193)

Discovery of Novel <i>N</i>‑Hydroxy-1,2,4-oxadiazole-5-formamides as ASM Direct Inhibitors for the Treatment of Atherosclerosis by Kan Yang (49193)

Discovery of Novel <i>N</i>‑Hydroxy-1,2,4-oxadiazole-5-formamides as ASM Direct Inhibitors for the Treatment of Atherosclerosis by Kan Yang (49193)

Discovery of Novel <i>N</i>‑Hydroxy-1,2,4-oxadiazole-5-formamides as ASM Direct Inhibitors for the Treatment of Atherosclerosis by Kan Yang (49193)

Discovery of Novel <i>N</i>‑Hydroxy-1,2,4-oxadiazole-5-formamides as ASM Direct Inhibitors for the Treatment of Atherosclerosis by Kan Yang (49193)